NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri

CME Course Description

Login to view
Course Activities.

Mark W. Stolar, MD; Alanna Morris MD, MSc, FHFSA; Robert J. Chilton, DO,

Speakers Affiliation

Course Director
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Mark W. Stolar, MD
Associate Professor of
Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Alanna Morris MD, MSc, FHFSA
Assistant Professor of Medicine Division of Cardiology
Emory Center for Heart
Failure Therapy
Emory University
Clinical Cardiovascular
Research Institute
Atlanta, GA

Robert J. Chilton, DO,
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas
Health Science Center
San Antonio, TX

Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH
Professor of Medicine
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA

Registration for this expired course is open for zero credits.

Type 2 Diabetes and Cardiovascular Disease: Decreasing the Risk
Activity/Course #:

Release/Start Date:
Nov 15 2017
Expiration Date:
Nov 14 2018
Target Audience:
Cardiologists and Primary Care Providers
Estimated Time To Complete CME Activity:
1.50 hours
Hardware/Software Requirements:
Internet Explorer, Firefox and Safari browsers (Chrome not supported at this time)
Long standing type 2 diabetes mellitus (T2DM) is associated with cardiovascular complications, and increased morbidity and mortality outcomes. Therefore, the optimal management of T2DM should not only aim at achieving glycemic control, but should also include the management of cardiovascular risk factors and associated CVD. Unfortunately, diabetes is increasing in prevalence in the U.S., and both glycemic and CVD risk control is generally suboptimal. Furthermore, cardiovascular risk in patients with diabetes may remain underrecognized and undertreated while clinicians are unaware of recent developments in evidence-based approaches to CVD event reduction.

In this 90-minute program, the program moderator Dr. Keith Ferdinand will interview 3 faculty thought leaders, Drs. Mark Stolar, Alanna Morris and Bob Chilton, to address the multiple issues facing patients with diabetes and the risks of cardiovascular disease. This educational program will discuss the increasing burden of comorbid cardiovascular disease including hypertension, dyslipidemia, CAD and HF in patients with diabetes as well as the evidence-based treatment of patients with diabetes and CVD, including the roles of available therapies for achieving glycemic goals and managing cardiovascular risk.

The program incorporates case based vignettes, didactic presentations, and an interactive discussion with audience participation to deliver information while increasing practitioner skills and confidence in patient evaluation and management. This webcast was recorded live and is being used with the permission of the presenters.

Topics and Learning Objectives

  1. Recognize the incidence of cardiovascular disease (CVD) and high-risk status in patients with diabetes, especially in certain racial/ethnic groups.
  2. Describe the public health implications of CVD in diabetes.
  3. Discuss the burden of comorbid CVD, including hypertension, dyslipidemia, coronary artery disease, and heart failure in patients with diabetes.
  4. Implement evidence-based treatment of patients with diabetes and cardiovascular disease.

How To Obtain Your CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.50 contact hours of continuing education (which includes 0.25 pharmacology hour).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Alanna Morris MD, MSc, FHFSA, Speaker serves as a consultant for Novartis.

Mark W. Stolar, MD, Speaker serves on the speaker/advisory board for Astra Zeneca.

Robert J. Chilton, DO, FACC, FAHA, Speaker serves as an advisor for Pfizer, MSD, Boehringer Ingelheim, and Lilly.

Keith Ferdinand, MD, FACC, FAHA, FNLA, Moderator serves as a consultant for Amgen, Sanofi, Novartis, Boehringer Ingelheim, and Quantum Genomics.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This is an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.